CITED4抗体;CITED4 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13087(CITED4 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The CITED4 (CBP/p300-interacting transactivator with glutamic acid/aspartic acid-rich carboxyl-terminal domain 4) antibody is a tool used to detect and study the CITED4 protein, a member of the CITED family of transcriptional co-regulators. CITED4 interacts with the transcriptional coactivators CBP (CREB-binding protein) and p300. modulating their activity in gene regulation. It is structurally characterized by its conserved C-terminal domain, which facilitates binding to CBP/p300. and is implicated in diverse cellular processes, including hypoxia response, cell proliferation, differentiation, and apoptosis. CITED4 is known to regulate pathways such as hypoxia-inducible factor (HIF) signaling and TGF-β/Smad signaling, often acting as a competitive inhibitor of other CITED proteins (e.g., CITED2) in these pathways.

Research highlights its dual roles in cancer: CITED4 may act as an oncogene or tumor suppressor depending on context. For instance, it is overexpressed in some cancers (e.g., breast cancer, hepatocellular carcinoma) where it promotes tumor growth and metastasis, while in others (e.g., glioblastoma), its downregulation correlates with poor prognosis. Antibodies against CITED4 are widely used in techniques like Western blotting, immunohistochemistry, and ChIP to analyze its expression, localization, and interactions. These studies help elucidate its tissue-specific functions, regulatory mechanisms, and therapeutic potential. However, inconsistencies in reported roles underscore the need for context-specific investigations to clarify its biological and pathological significance.